Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Long-term safety

PTH-066 Post-marketing experience of vedolizumab: pneumonia and other respiratory tract infections
F Bhayat, A Blake, SP Travis

Gut Jul 2017, 66 (Suppl 2) A238-A239; DOI: 10.1136/gutjnl-2017-314472.465
AODWE-002 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of gemini 1 completers rolling into the gemini open-label extension study
A Kaser, A James, on behalf of the GEMINI open-label extension study authors

Gut Jul 2017, 66 (Suppl 2) A120; DOI: 10.1136/gutjnl-2017-314472.237
AODWE-003 Long-term effectiveness and safety of vedolizumab in patients with crohn’s disease: 5-year cumulative exposure of gemini 2 completers rolling into the gemini open-label extension study
A Kaser, A James, on behalf of the GEMINI open-label extension study authors

Gut Jul 2017, 66 (Suppl 2) A121; DOI: 10.1136/gutjnl-2017-314472.238
AODTH-003 Vedolizumab clinical and post-marketing safety experience of opportunistic infections
SC Ng, W Palo, A Blake, Q Rana-Khan, F Bhayat

Gut Jul 2017, 66 (Suppl 2) A200; DOI: 10.1136/gutjnl-2017-314472.390
PTH-068 Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case series
M Zerôncio, A Blake, Q Rana-Khan, W Palo, F Bhayat

Gut Jul 2017, 66 (Suppl 2) A240; DOI: 10.1136/gutjnl-2017-314472.467
PTH-067 Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment: clinical trial experience
BG Feagan, F Bhayat, JM Khalid, W Palo, A Blake, M Shetzline, SP Travis

Gut Jul 2017, 66 (Suppl 2) A239-A240; DOI: 10.1136/gutjnl-2017-314472.466